Page 58 - HIV/AIDS Guidelines

92. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent
antiretroviral therapy: CHARTER Study. Neurology. Dec 7 2010;75(23):2087-2096.
93. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex.
Neurology. May 1988;38(5):794-796.
94. Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human
immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER
Study. Arch Neurol. May 2010;67(5):552-558.
95. Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS. Apr 24
2011;25(7):919-928.
96. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Response to
combination antiretroviral therapy: variation by age. AIDS. Jul 31 2008;22(12):1463-1473.
97. Nogueras M, Navarro G, Anton E, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-
infected patients diagnosed at the age of 50 or more. BMC Infect Dis. 2006;6:159.
98. Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. Pretreatment factors associated with 3-year (144-week)
virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr. Mar 1
2007;44(3):268-277.
99. Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class.
AIDS. Oct 23 2010;24(16):2469-2479.

100.Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human
immunodeficiency virus type 1. N Engl J Med. Jan 18 1990;322(3):166-172.

101.Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration
of HIV-1 infection. J Acquir Immune Defic Syndr. Apr 1 2002;29(4):346-355.

102.Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+
T-cell changes independent of viral load. Blood. Aug 15 2004;104(4):942-947.

103.Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection
is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor
usage. J Infect Dis. Apr 1999;179(4):859-870.
104.Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with
progression to AIDS. AIDS. Sep 5 2003;17(13):1881-1888.
105.Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after
initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr.
Aug 1 2006;42(4):426-434.
106.Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human
immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis.
May 15 2003;187(10):1534-1543.
107.Neuhaus J, Jacobs DR, Jr., Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in
adults with HIV infection. J Infect Dis. Jun 15 2010;201(12):1788-1795.
108.Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in
patients with moderately advanced disease. AIDS. Sep 27 2002;16(14):1859-1866.
109.Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral
therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. Feb 1 2009;48(3):350-361.
110.Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict
functional responses to immunizations in chronic HIV-1 infection. AIDS. Sep 26 2003;17(14):2015-2023.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents E-17

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.